David A Flockhart
Overview
Explore the profile of David A Flockhart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
5514
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kadakia K, Kidwell K, Seewald N, Snyder C, Storniolo A, Otte J, et al.
Breast Cancer Res Treat
. 2017 Apr;
164(2):411-419.
PMID: 28451964
Purpose: Aromatase inhibitors (AI), which decrease circulating estradiol concentrations in post-menopausal women, are associated with toxicities that limit adherence. Approximately one-third of patients will tolerate a different AI after not...
2.
Tisdale J, Jaynes H, Overholser B, Sowinski K, Flockhart D, Kovacs R
JACC Clin Electrophysiol
. 2017 Apr;
2(7):765-774.
PMID: 28451647
Objectives: We tested the hypothesis that oral progesterone administration attenuates drug-induced QT interval lengthening. Background: Evidence from preclinical and human investigations suggests that higher serum progesterone concentrations may be protective...
3.
Robarge J, Desta Z, Nguyen A, Li L, Hertz D, Rae J, et al.
Breast Cancer Res Treat
. 2016 Dec;
161(3):453-461.
PMID: 27943008
Purpose: Inter-individual differences in estrogen concentrations during treatment with aromatase inhibitors (AIs) may contribute to therapeutic response and toxicity. The aim of this study was to determine plasma concentrations of...
4.
Zhao L, Jin H, Liu J, Skaar T, Ipe J, Lv W, et al.
Bioorg Med Chem
. 2016 Sep;
24(21):5400-5409.
PMID: 27647367
The design and synthesis of dual aromatase inhibitors/selective estrogen receptor modulators (AI/SERMs) is an attractive strategy for the discovery of new breast cancer therapeutic agents. Previous efforts led to the...
5.
Desta Z, Metzger I, Thong N, Lu J, Callaghan J, Skaar T, et al.
Antimicrob Agents Chemother
. 2016 Sep;
60(11):6813-6822.
PMID: 27600044
Cytochrome P450 2B6 (CYP2B6) metabolizes clinically important drugs and other compounds. Its expression and activity vary widely among individuals, but quantitative estimation is hampered by the lack of safe and...
6.
Kreutz R, Breall J, Sinha A, von der Lohe E, Kovacs R, Flockhart D
Clin Pharmacol
. 2016 Jun;
8:45-50.
PMID: 27350760
Background: Reloading with high-dose atorvastatin shortly before percutaneous coronary interventions (PCIs) has been proposed as a strategy to reduce periprocedural myonecrosis. There has been a concern that statins that are...
7.
Leonard C, Han X, Bilker W, Flory J, Brensinger C, Flockhart D, et al.
Diabetes Res Clin Pract
. 2016 Jun;
115:60-7.
PMID: 27242124
We conducted high-dimensional propensity score-adjusted cohort studies to examine whether thiazolidinedione use with a statin or fibrate was associated with an increased risk of severe hypoglycemia. We found that concomitant...
8.
Hertz D, Deal A, Ibrahim J, Walko C, Weck K, Anderson S, et al.
Oncologist
. 2016 May;
21(7):795-803.
PMID: 27226358
Background: Polymorphic CYP2D6 is primarily responsible for metabolic activation of tamoxifen to endoxifen. We previously reported that by increasing the daily tamoxifen dose to 40 mg/day in CYP2D6 intermediate metabolizer...
9.
Robarge J, Duarte D, Shariati B, Wang R, Flockhart D, Vasko M
Exp Neurol
. 2016 Apr;
281:53-65.
PMID: 27072527
Although aromatase inhibitors (AIs) are commonly used therapies for breast cancer, their use is limited because they produce arthralgia in a large number of patients. To determine whether AIs produce...
10.
Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers
Cho D, Shen J, Lemler S, Skaar T, Li L, Blievernicht J, et al.
Drug Metab Pharmacokinet
. 2016 Apr;
31(2):107-16.
PMID: 27053325
The effect of rifampin on the in vivo metabolism of the antiretroviral drug efavirenz was evaluated in healthy volunteers. In a cross-over placebo control trial, healthy subjects (n = 20)...